← All trials
NCT04658420
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2020
- Primary completion
- Dec 31, 2022
- Completion date
- Apr 30, 2023
- First posted
- Dec 8, 2020
- Last posted
- Dec 8, 2020
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas, TylerLead sponsor
- University of Texas at HoustonCollaborator
- National Institutes of Health (NIH)Collaborator
- University of Texas, TylerOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.